ArticleAntimicrobial agents and chemotherapy2018
Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 58 citations in OpenAlex.
- HBV p22-interacting protein C1QBP inhibits viral replication through impeding nucleocapsid formation and nuclear import.PLoS pathogens · 2025Article
- Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening.Acta pharmaceutica Sinica. B · 2024Article
- RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects.Microorganisms · 2024Review
- Hepatitis B: Model Systems and Therapeutic Approaches.Journal of immunology research · 2024Review
- Recent Advances in the Development of Sulfamoyl-Based Hepatitis B Virus Nucleocapsid Assembly Modulators.Viruses · 2023Review
- Identification of novel tetrahydroquinoxaline derived phenyl ureas as modulators of the hepatitis B virus nucleocapsid assembly.European journal of medicinal chemistry · 2023Article
- Development of anti-HBV agents targeting HBV capsid proteins.RSC medicinal chemistry · 2023Article
- Binding characteristics of pyrrole-scaffold hepatitis B virus capsid inhibitors and identification of novel potent compounds.RSC advances · 2023Article
- Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.Antimicrobial agents and chemotherapy · 2023Article
- A fragment-based drug discovery developed on ciclopirox for inhibition of Hepatitis B virus core protein: An in silico study.PloS one · 2023Article
- The identification of highly efficacious functionalised tetrahydrocyclopenta[RSC medicinal chemistry · 2022Article
- 4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.Bioorganic & medicinal chemistry letters · 2022Article
- Structure-Based Discovery ofViruses · 2022Article
- Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy.Molecules (Basel, Switzerland) · 2021Review
- Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure.World journal of gastroenterology · 2021Review
- Recent Advances in Hepatitis B Treatment.Pharmaceuticals (Basel, Switzerland) · 2021Review
- GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein.Nature communications · 2021Article
- Synthesis of 4-oxotetrahydropyrimidine-1(2H)-carboxamides derivatives as capsid assembly modulators of hepatitis B virus.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2021Article
- Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731.Antimicrobial agents and chemotherapy · 2020Article
- Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379.Antimicrobial agents and chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 3 institutions in 2 countries.
Nagraj ManiArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada nmani@arbutusbio.com.ORCID 0000-0002-8446-2338
Andrew G ColeArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Janet R PhelpsArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Andrzej ArdzinskiArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Kyle D CobarrubiasArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Andrea CuconatiArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Bruce D DorseyArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Ellen EvangelistaArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Kristi FanArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Fang GuoArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Haitao GuoIndiana University, Indianapolis, Indiana, USA.
Ju-Tao GuoBaruch S. Blumberg Institute, Doylestown, Pennsylvania, USA.
Troy O HarasymArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Salam KadhimArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Steven G KultgenArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Amy C H LeeArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Alice H L LiArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Quanxin LongIndiana University, Indianapolis, Indiana, USA.
Sara A MajeskiArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Richeng MaoIndiana University, Indianapolis, Indiana, USA.
Kevin D McClintockArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Stephen P ReidArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Rene RijnbrandArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Nicholas M SneadArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Holly M Micolochick SteuerArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Kim SteverArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Sunny TangArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Xiaohe WangArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Qiong ZhaoBaruch S. Blumberg Institute, Doylestown, Pennsylvania, USA.
Michael J SofiaArbutus Biopharma Inc., Warminster, Pennsylvania, USA, and Burnaby, British Columbia, Canada.
Arbutus Biopharma (Canada) · CAIndiana University – Purdue University Indianapolis · USBaruch S. Blumberg Institute · US
Funding
Molecular Mechanisms of HBV cccDNA FormationR01AI110762 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2016 to 2025
$3.5MDevelopment of a novel drug candidate that inhibits hepatitis B virus covalentlyR01AI094474 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI GUO, HAITAO · 2011 to 2015
$3.4MDevelopment of an HTS Assay for Discovery of HBV cccDNA InhibitorsR01AI123271 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2017 to 2019
$1.2MNIAID NIH HHS R01 AI094474NIAID NIH HHS R01 AI110762NIAID NIH HHS R01 AI123271
Abstract
AB-423 is a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors in phase 1 clinical trials. In cell culture models, AB-423 showed potent inhibition of HBV replication (50% effective concentration [EC
Indexed as
AnimalsAntiviral AgentsBinding SitesCapsidCell Line, TumorDNA, CircularDNA, ViralFemaleGuanineHepatitis BHepatitis B virusHumansMiceMolecular Docking SimulationProtein BindingRNA, ViralAntiviral AgentsDNA, CircularDNA, ViralentecavirGuanineRNA, ViralAB-423capsid inhibitorCHBHBVpgRNA encapsidationsulfamoylbenzamide
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.